CAMBRIDGE, UK—A new blood test promises quicker assessment of treatment efficacy in patients with metastatic breast cancer. Dr Dana Tsui and colleagues from the Cancer Research UK Cambridge Institute, University of Cambridge, report in the New...
AudioMedica News Circulating free tumour DNA test could guide breast cancer therapy Play Episode Pause Episode 1x 00:00 / Subscribe RSS Feed CAMBRIDGE, UK—A new blood test promises quicker assessment of treatment efficacy in patients with metastatic...
AudioMedica News Dog walking cuts breast cancer recurrence risk Play Episode Pause Episode 1x 00:00 / Subscribe RSS Feed Walking a dog most days could cut down your risk of having a recurrence of breast cancer, according to research presented at the...
AudioMedica News Which patients for bisphosphonate control of breast cancer metastasis? Play Episode Pause Episode 1x 00:00 / Subscribe RSS Feed ST GALLEN, SWITZERLAND—Bisphosphonates have an important part to play in managing breast cancer...
AudioMedica News Is breast cancer screening oversold? Play Episode Pause Episode 1x 00:00 / Subscribe RSS Feed ST GALLEN, SWITZERLAND—The controversy about the effectiveness of mammographic screening was aired at the 2013 conference on “Primary...
AudioMedica News Low risk prostate cancer: scope and benefits from reducing overtreatment Play Episode Pause Episode 1x 00:00 / Subscribe RSS Feed ORLANDO, FLORIDA—Patients with low-risk prostate cancer are more likely to die with their disease than...
AudioMedica News Enzalutamide in metastatic castration resistant prostate cancer: over 75s benefit too Play Episode Pause Episode 1x 00:00 / Subscribe RSS Feed ORLANDO, FLORIDA—Men over 75 were safely and effectively treated for their metastatic...
AudioMedica News Low risk localized prostate cancer: no harm from waiting! Play Episode Pause Episode 1x 00:00 / Subscribe RSS Feed ORLANDO, FLORIDA—A decision to delay surgery or radiotherapy for early prostate cancer is in the best interests of...
AudioMedica News Androgen blockade: 18 as good as 36 months in radiotherapy-treated prostate cancer Play Episode Pause Episode 1x 00:00 / Subscribe RSS Feed ORLANDO, FLORIDA—Patients receiving radiotherapy for high-risk node-negative prostate cancer...
ORLANDO, FLORIDA—A decision to delay surgery or radiotherapy for early prostate cancer is in the best interests of most patients according to research presented to the 2013 Genitourinary Cancers Symposium
ORLANDO, FLORIDA—Patients with low-risk prostate cancer are more likely to die with their disease than of it, according to Dr Ayal Aizer from the Brigham and Women’s Hospital,
ORLANDO, FLORIDA—Patients receiving radiotherapy for high-risk node-negative prostate cancer benefit as much from 18 months of androgen blockade as from the usual 36 months